Balanced news tone
News Sentiment
TNYA sentiment intelligence
Tenaya Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+10.6% over one week, +22.3% over four weeks, trend active, and below fair value.
Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Tenaya to unveil TN-201 gene therapy HCM trial data June 3, 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jun 2026 07:00
- Source
- Stock Titan
Tenaya Therapeutics (TNYA) director receives 120,000 stock options at $0.7989
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Stock Titan
Tenaya Therapeutics (TNYA) director granted 120,000 options at $0.7989 strike
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Stock Titan
Tenaya (TNYA) director receives 120K stock options at $0.7989
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Stock Titan
Tenaya Therapeutics to Present at Jefferies Global Healthcare Conference June 2026 | TNYA Stock News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 07:00
- Source
- Quiver Quantitative
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 13 May 2026 07:00
- Source
- Moomoo
Why Tenaya Therapeutics (TNYA) Is Up 26.6% After New TN-401 Data Near-Term Catalysts
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Tenaya Therapeutics (TNYA) Is Up 26.6% After TN-401 Data Buzz and Narrower Losses Has The Bull Case Changed?
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 11 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Tenaya Therapeutics (TNYA) Valuation Check As TN-401 Gene Therapy Data Approaches ASGCT 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 May 2026 07:00
- Source
- simplywall.st
Should I buy Tenaya Therapeutics (TNYA)
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 06 May 2026 07:00
- Source
- Zacks Investment Research
Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- GlobeNewswire
Two heart gene therapy readouts near as Tenaya adds Alnylam deal
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
Tenaya Therapeutics, Inc. (TNYA) Reports Q1 Loss, Misses Revenue Estimates
- Tone
- Negative 18/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Market source
We Think Tenaya Therapeutics (NASDAQ:TNYA) Needs To Drive Business Growth Carefully
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 May 2026 07:00
- Source
- simplywall.st
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
William Blair Analysts Confident on Tenaya Therapeutics (TNYA) Product Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 24 Mar 2026 07:00
- Source
- Market source
Tenaya Therapeutics (TNYA) Is Up 47.7% After Positive TN-301 DMD Data And Alnylam Deal
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 12 Mar 2026 07:00
- Source
- Market source
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 Mar 2026 07:00
- Source
- Investing News Network
Morgan Stanley Backs Tenaya Therapeutics (TNYA) as SMID-Cap Biotech Primed to Outperform in 2026
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 19 Jan 2026 08:00
- Source
- Market source
Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Dec 2025 08:00
- Source
- Market source